Growth and Returns
Thessalus is focused on achieving significant risk-adjusted returns for investors through strategic transactions in middle and large market cap life sciences companies based in the U.S. and internationally. Target performance is 20-25% annual growth. Target performance met and exceeded since fund inception.
